What is the appropriate dose of Aygestin (medroxyprogesterone acetate) for treating metrorrhagia?

Aygestin Dosing for Metrorrhagia

For acute metrorrhagia, use medroxyprogesterone acetate (MPA) 10-20 mg daily for 10-14 days per cycle, with higher doses (60-120 mg on day 1, then 20 mg daily for 10 days) reserved for severe bleeding requiring hospitalization.

Standard Dosing Regimen

The typical approach for metrorrhagia involves cyclic MPA at 10-20 mg daily for 10-14 days per month 1. This regimen is effective for most premenopausal women with abnormal uterine bleeding and can be continued for 3-5 months.

Timing Considerations

Recent evidence suggests that 10-day administration (days 16-25 of cycle) is superior to 15-day administration (days 11-25) for achieving menstrual regularity and stopping abnormal bleeding 2. The shorter duration protocol:

• More frequently stops abnormal bleeding
• Better regulates menstrual cycles
• Requires only 3 cycles to achieve bleeding cessation

Acute/Severe Bleeding Protocol

For adolescents or women hospitalized with severe metrorrhagia and anemia, use an aggressive loading approach 3:

• Day 1: 60-120 mg total dose (divided throughout the day)
• Days 2-11: 20 mg daily

This high-dose regimen achieves:

• Bleeding cessation in 25% within 24 hours
• Complete cessation in 75% by day 4
• Effectiveness correlates with initial hemoglobin (lower hemoglobin = longer time to cessation)

Important Clinical Considerations

Patient Selection Factors

Treatment satisfaction and continuation are influenced by 1:

• Age ≥35 years: Higher satisfaction (OR 2.67)
• Desire for uterine conservation: Better outcomes
• Tubal sterilization: Lower satisfaction (OR 0.52)
• Patients wanting definitive resolution may be better candidates for alternative treatments

Common Pitfalls

• The 2024 CDC contraceptive guidelines 4 do not specifically address MPA for metrorrhagia treatment, focusing instead on bleeding management in contraceptive users
• Side effects (headaches, vaginal bleeding) occur in a significant proportion and lead to discontinuation in 6-21% of patients 5
• Completion rates: only 65% complete 3 months of therapy 1

Duration of Treatment

• Initial trial: 3-5 months 1
• Reassess after 3 cycles with the 10-day protocol 2
• Consider alternative treatments if inadequate response or patient dissatisfaction

Algorithm for Dosing Selection

1. Severe bleeding + anemia requiring hospitalization: Use high-dose protocol (60-120 mg day 1, then 20 mg × 10 days) 3

2. Moderate metrorrhagia, outpatient setting: Use cyclic MPA 10-20 mg daily for days 16-25 of cycle 2

3. Adjust based on response: If bleeding persists after 3 cycles, consider increasing dose to 20 mg or switching to alternative therapy

4. Patient counseling: Set expectations about 3-5 month treatment duration and discuss that only 57% achieve satisfaction with this approach 1